| Autor: |
Bea, C. Ortigosa, Pérez Ginés, B., Abad Bouzán, C. |
| Předmět: |
|
| Zdroj: |
European Psychiatry; 2022 Special issue S1, Vol. 63, pS551-S551, 1/4p |
| Abstrakt: |
Introduction: Data on the use of clozapine and injectable antipsychotics in patients with schizophrenia has been a study source in several articles in recent years, demonstrating heterogeneity and a big variability in the prescriptions. Objectives: Our goal is to compare these data with those obtained in Calatayud's Region, assess whether there are differences to initiate future strategies to be proposed. Methods: We access and review data on clozapine consumption and use of depot treatment in patients diagnosed with schizophrenia and under follow-up by the Calatayud Mental Health Unit. Results: Patients diagnosed with schizophrenia in this territory compromise around 0.21% of their total population (64.3% men and 35.7% women). The mean age of the user is 49.85 years, the median and the mode 50 years. Patients diagnosed with schizophrenia on treatment with Clozapine are 13.1% of patients under treatment, 41.7% use Depot injections and 2.38% of patients use both. Conclusions: Global prescribing data for Clozapine and Depot injections in patients diagnosed with schizophrenia in the area we studied (Calatayud) are similiar to data collected in other national studies. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
